CryoPort (NASDAQ:CYRX) Sets New 12-Month High – Should You Buy?

CryoPort, Inc. (NASDAQ:CYRX)’s stock price reached a new 52-week high during trading on Thursday . The company traded as high as $11.45 and last traded at $11.2870, with a volume of 92876 shares changing hands. The stock had previously closed at $10.98.

Wall Street Analyst Weigh In

CYRX has been the topic of several research analyst reports. Weiss Ratings restated a “sell (d+)” rating on shares of CryoPort in a research note on Monday, December 29th. Needham & Company LLC increased their price objective on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Finally, UBS Group raised their target price on shares of CryoPort from $11.00 to $12.50 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, CryoPort has an average rating of “Moderate Buy” and a consensus price target of $12.83.

CryoPort Trading Up 1.1%

The stock has a market cap of $556.03 million, a P/E ratio of 9.49 and a beta of 1.54. The firm’s 50 day moving average price is $9.72 and its 200-day moving average price is $9.14. The company has a debt-to-equity ratio of 0.40, a current ratio of 15.77 and a quick ratio of 15.01.

CryoPort (NASDAQ:CYRX) last posted its earnings results on Tuesday, November 4th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. The business had revenue of $44.23 million during the quarter, compared to analyst estimates of $41.22 million. CryoPort had a negative return on equity of 11.07% and a net margin of 35.57%. As a group, equities research analysts forecast that CryoPort, Inc. will post -0.99 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Ramkumar Mandalam sold 11,570 shares of the business’s stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $9.99, for a total transaction of $115,584.30. Following the completion of the transaction, the director directly owned 80,758 shares in the company, valued at approximately $806,772.42. The trade was a 12.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 10.00% of the company’s stock.

Institutional Investors Weigh In On CryoPort

Several hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company grew its holdings in CryoPort by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock worth $136,000 after acquiring an additional 1,557 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of CryoPort by 299.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company’s stock valued at $27,000 after purchasing an additional 2,729 shares in the last quarter. State of Wyoming increased its holdings in CryoPort by 30.2% during the second quarter. State of Wyoming now owns 14,218 shares of the company’s stock valued at $106,000 after buying an additional 3,301 shares during the period. Intech Investment Management LLC lifted its holdings in CryoPort by 14.6% during the second quarter. Intech Investment Management LLC now owns 25,951 shares of the company’s stock worth $194,000 after buying an additional 3,305 shares during the period. Finally, Franklin Resources Inc. boosted its position in CryoPort by 0.9% during the second quarter. Franklin Resources Inc. now owns 394,420 shares of the company’s stock valued at $2,942,000 after purchasing an additional 3,710 shares in the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

CryoPort Company Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.